[ ]
The Prostate Cancer Fund

OneinEight

Ventures
Persistent demand. Multiple shapes.
A $100M venture fund — built by leaders in prostate cancer research.
scroll
1in8 is a $100M Venture Fund built by Leaders in Prostate Cancer Research to seed and fund companies aiming to eliminate prostate and related cancers as a cause of death and suffering.
Target Fund

$100M

15–20 companies · seed to Series A · early-stage portfolio.

Built by Leaders

Expert-Led

5 founding KOLs · ~50% of approved PCa drugs trace back to their networks.

Cure-Focused

One Disease

Anchored in prostate. Extends to cross-cancer where the science maps.

]
Why Now · The Inflection Point

Discovery exploding.
Clinical development steady state.

Capital flooded discovery for two decades. Molecules now arrive at machine pace. What hasn't scaled is the engine that decides which deserve a patient. This is a structural gap, not a temporary trend.

~6×
Discovery output
Annual novel-molecule disclosures up roughly 6× since 2005 — China alone now ~1/3 of global IND filings.
<10%
Reach Phase 3
Of all candidates entering clinical, fewer than 1 in 10 reach pivotal trials. The bottleneck has migrated to development.
A consistently
hungry market
Persistent buyer demand
Buyers exist. Molecules exist. The missing piece is the disciplined development infrastructure between them — and the demand renews every cycle.
The
opportunity
1in8's role
Build a more intelligent, compressed development engine — one that sorts the morass, designs clinical programs, and manages burn.
Founder · Scientific Advisory Committee

Five active KOLs.
Not advisors at the margin.

Direct clinical and development experience across the AR-pathway, PARP, hormonal, and radiopharma classes — drug-approval studies they led include Rubraca, Pluvicto, Xofigo, Nubeqa, Orgovyx, Zytiga, and Xtandi.

Dr. Charles Ryan
Charles J. Ryan, MD
Founder · Chief Scientific Advisor · MSKCC
Neal Shore
Neal Shore, MD FACS
Carolina Urology
Oliver Sartor
Oliver Sartor, MD
Mayo · Tulane
Ganesh Raj
Ganesh Raj, MD
UT Southwestern
Marco Gottardis
Marco Gottardis, PhD
Former J&J · Gottardis Biotech

100+ collective years across drug approval, clinical leadership, and pharma corporate development. IC inputs on every deal.

[
Clinical Engine · Since 2005

Execution infrastructure already in place.

The Prostate Cancer Clinical Trials Consortium runs early-phase PCa trials at scale. Dr. Ryan has been a member since 2006 and Medical Director since 2024 — giving portfolio companies direct access to discounted trial execution in exchange for warrants and portfolio terms.

332
Studies since 2005
17,780 patients accrued across PCCTC's trial history.
13
FDA approvals
Drugs with PCCTC study contributions in their approval path.
Dr. Ryan — PCCTC member since 2006 · Medical Director since 2024. The operational thread connecting fund, founder, and clinical engine. Portfolio trials route through PCCTC; discounted execution for 1in8 companies; warrants and portfolio terms in exchange for capacity.
]
Thesis · Diagram One

The flywheel.

A self-reinforcing system of proprietary sourcing, investment, clinical execution, and commercial partnership — generating NewCos with higher ownership and shorter liquidity pathways than a traditional multi-LP biotech fund can offer.

01 · Source
KOLs
5 founding KOLs · 25-yr clinical network across prostate & urological oncology. Expert-led, not expert-informed.
02 · Allocate
IC
$100M, clean 2/20. ~15–20 seed & Series A checks. 50% reserved for follow-ons.
03 · Execute
CRO
PCCTC spinout · ~$25M revenue book. Trials for portfolio & third parties.
04 · Partner
Pharma
Anchor LP relationships with ongoing strategic partner dialogue. Strategic without the cage.
05 · Output
NewCos
Higher ownership. Shorter liquidity via a direct listing partner.

De-risked sourcing. Baked-in commercial partner. NewCos with higher ownership and a shorter path to liquidity.

[ ]
Let's Build

Let's build what's next, together.

The deck walks the full thesis. The conversation starts when you reach out.

Contact Us Command Center →
Founder · CSA
Charles J. Ryan, MD
Founder · Chief Scientific Advisor
chuck@nxp.vc
+1 (415) 269-4879
General Partner
Christian Gammill
General Partner · NXP
gammill@nxp.vc
+1 (917) 826-0078